FUDANZHANGJIANG (688505.SH): Aminolevulinic Acid Hydrochloride Granules for Visualization in Bladder Cancer Surgery Receives Drug Marketing Application Acceptance Notice

date
18:27 19/11/2026
avatar
GMT Eight
FudanZhangjiang (688505.SH) announced that the company recently received the "Notice of Acceptance" issued upon approval by the National Medical Products Administration. The marketing application for the aminolevulinic acid hydrochloride granules developed by the company for adjunctive use in surgical resection of non-muscle-invasive bladder cancer has been accepted. If the drug is approved for marketing in the future, it will further enrich the company's product pipeline and enhance the company's overall competitiveness.
FUDANZHANGJIANG (688505.SH) announced that the company recently received the "Acceptance Notice" approved and issued by the National Medical Products Administration. The marketing application for the aminolevulinic acid hydrochloride granules developed by the company for adjuvant use in surgical resection of non-muscle-invasive bladder cancer has been accepted. If the drug is approved for marketing in the future, it will further enrich the company's product line and enhance the company's overall competitiveness.